YaoGeJu

Company directoryChina company filings

Zhejiang Hisoar Pharmaceutical Co., Ltd.

As of 18 November 2026, for the company name Zhejiang Hisoar Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 5 active records with this name as holder; 5 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

13 acceptance records as first applicant, grouped into 7 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Empagliflozin Tablets 2 records · Latest accepted 2026/09/01

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2602179Generic2026/09/01Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
CYHS2602178Generic2026/09/01Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Meropenem for Injection 2 records · Latest accepted 2025/05/20

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2501827Generic2025/05/20Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
CYHS2501826Generic2025/05/20Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Repaglinide Tablets 2 records · Latest accepted 2025/02/27

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500856Generic2025/02/27Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
CYHS2201243Generic2022/08/05Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Dapagliflozin Tablets 2 records · Latest accepted 2025/01/11

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500263Generic2025/01/11Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
CYHS2500262Generic2025/01/11Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Pantoprazole Enteric-Coated Tablets 3 records · Latest accepted 2022/06/13

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200869Generic2022/06/13Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
CYHS2200868Generic2022/06/13Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
CYHS2101452Generic2021/07/20Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Voglibose Tablets 1 records · Latest accepted 2021/12/28

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2102303Generic2021/12/28Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Clindamycin Hydrochloride Capsules 1 records · Latest accepted 2021/09/13

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2140526Supplement2021/09/13Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗

Changes in the last 90 days

2 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Accepted: 2 applications

  1. 2026/09/01Accepted

    Empagliflozin Tablets

    CYHS2602179

    Fact date: 2026/09/01 · Date added to this site: 2026/10/22

    View source ↗
  2. 2026/09/01Accepted

    Empagliflozin Tablets

    CYHS2602178

    Fact date: 2026/09/01 · Date added to this site: 2026/10/22

    View source ↗

Under review

4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Empagliflozin Tablets CYHS2602179Generic2026/09/01Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Empagliflozin Tablets CYHS2602178Generic2026/09/01Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Meropenem for Injection CYHS2501827Generic2025/05/20Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗
Meropenem for Injection CYHS2501826Generic2025/05/20Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗

Catalogue holder records

5 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Pantoprazole Enteric-Coated TabletsZhejiang Hisoar Pharmaceutical Co., Ltd.Zhejiang Hisoar Pharmaceutical Co., Ltd.国药准字H202343602023/10/24Generic approved under the new chemical-drug registration classificationCDE ↗
Pantoprazole Enteric-Coated TabletsZhejiang Hisoar Pharmaceutical Co., Ltd.Zhejiang Hisoar Pharmaceutical Co., Ltd.国药准字H202343652023/10/24Generic approved under the new chemical-drug registration classificationCDE ↗
Voglibose TabletsZhejiang Hisoar Pharmaceutical Co., Ltd.Zhejiang Hisoar Pharmaceutical Co., Ltd.国药准字H202339092023/07/06Generic approved under the new chemical-drug registration classificationCDE ↗
Clindamycin Hydrochloride CapsulesZhejiang Hisoar Pharmaceutical Co., Ltd.Zhejiang Hisoar Pharmaceutical Co., Ltd.国药准字H202170012022/02/25Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Clindamycin Hydrochloride CapsulesZhejiang Hisoar Pharmaceutical Co., Ltd.Zhejiang Hisoar Pharmaceutical Co., Ltd.国药准字H201630832021/01/06Drug that passed quality-and-efficacy consistency evaluationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

5 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
他克莫司 · No verified English nameZhejiang Hisoar Pharmaceutical Co., Ltd.Y20250000882I2025/09/02CDE ↗
地夸磷索钠 · No verified English nameZhejiang Hisoar Pharmaceutical Co., Ltd.Y20240000710A2026/05/20CDE ↗
盐酸阿莫罗芬 · No verified English nameZhejiang Hisoar Pharmaceutical Co., Ltd.Y20190009340A2025/03/18CDE ↗
吗氯贝胺 · No verified English nameZhejiang Hisoar Pharmaceutical Co., Ltd.Y20190003574A—CDE ↗
伏格列波糖 · No verified English nameZhejiang Hisoar Pharmaceutical Co., Ltd.Y20190002236A2024/08/23CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

1 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Vortioxetine Hydrobromide Tablets CYHS2503642Generic2025/10/14Shanghai Gu Fang Meng Pharmaceuticals Technology Co., Ltd. romanized; Zhejiang Hisoar Pharmaceutical Co., Ltd.CDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.